GranuFlo and NaturaLyte are drugs used in kidney dialysis procedures. These drugs are used in concert during kidney dialysis to eliminate the normal blood acid buildup. Millions of Americans suffering from chronic kidney failure rely on hemodialysis for survival. Fresenius Medical Care, the largest dialysis provider and manufacturer in the U.S. requires the use of GranuFlo in its system and facilities.


During hemodialysis the kidneys are not able to filter out and neutralize typical blood acid. GranuFlo and NaturaLyte powders are sodium diacetate-based and function to supplement functionality for the kidneys. Unfortunately, the liver converts the active ingredients to bicarbonate resulting in excessive levels in the blood stream. High bicarbonate levels can lead to sudden heart attack and other serious conditions.


In November of 2011 an internal Fresenius memo alerts of the dangerous risks of heart attack tied to GranuFlo and NaturaLyte; however, the company does not issue warnings to patients or doctors. Less than one year later, in May 2012 a class I FDA recall is initiated warning of the risks including death.


Studies have revealed that a large number of patients who were given GranuFlo and NaturaLyte suffered heart attacks and that usage carried approximately six times the risk. If you or someone you know has received dialysis treatment and suffered a heart attack or other adverse side effects, you should seek legal counsel immediately. The irresponsibility on the part of the manufacturers is egregious, and patients and their families should understand the risks and how to protect themselves.